- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-4598
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 ; volume:18 ; number:1 ; day:6 ; month:11 ; year:2019 ; pages:1-14 ; date:12.2019
Molecular cancer ; 18, Heft 1 (6.11.2019), 1-14, 12.2019
- Creator
-
Qin, Shuang
Xu, Linping
Yi, Ming
Yu, Shengnan
Wu, Kongming
Luo, Suxia
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12943-019-1091-2
- URN
-
urn:nbn:de:101:1-2020030317540630147430
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Qin, Shuang
- Xu, Linping
- Yi, Ming
- Yu, Shengnan
- Wu, Kongming
- Luo, Suxia
- SpringerLink (Online service)
Other Objects (12)
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Moving Beyond the Asylum Muddle
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Moving Beyond the Asylum Muddle
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
The CTLA ‐4 immune checkpoint protein regulates PD‐L1: PD ‐1 interaction via transendocytosis of its ligand CD80
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Moving Beyond the Asylum Muddle